Hjelmgren J, Berggren F, Andersson F
AstraZeneca R & D Lund, Clinical Science, Health Economics & Outcomes Research, SE-221 87 Lund, Sweden.
Value Health. 2001 May-Jun;4(3):225-50. doi: 10.1046/j.1524-4733.2001.43040.x.
To classify, summarize, and compare the health economic guidelines (HE) issued in Europe, North America, and Australia to clarify similarities and differences between them.
In a literature review HE guidelines were classified according to whether they were 1) formalized, 2) informal, or 3) guidelines for health economic methods. All the guidelines were summarized in a table format according to 15 important methodological aspects. The aspects were compared both within and between the three groups.
A total of 25 guidelines were identified, seven formalized, eight informal, and 10 guidelines for HE methods. The levels of agreement for methodological aspects within groups were 40% to 100%, 25% to 100% and 30% to 100% for the formalized, informal, and HE guidelines, respectively. The formal guidelines were slightly more homogenous than the other groups. The between-group comparison showed that the guidelines were in agreement for about 75% of methodological aspects. Disagreement between guidelines was found in choice of perspective, resources, and costs that should be included in the analysis, and in methods of evaluating resources used.
A harmonization of methodological requirements and recommendations exists both within and between the guideline groups. This review provides information concerning the core of agreements that have been reached. A number of policy implications for various parties, mainly the pharmaceutical industry, were identified.
对欧洲、北美和澳大利亚发布的卫生经济指南进行分类、总结和比较,以阐明它们之间的异同。
在文献综述中,卫生经济指南根据其是否为1)正式的、2)非正式的或3)卫生经济方法指南进行分类。所有指南均根据15个重要的方法学方面以表格形式进行总结。对这三个组内和组间的这些方面进行了比较。
共识别出25份指南,7份正式指南、8份非正式指南以及10份卫生经济方法指南。正式指南、非正式指南和卫生经济指南在组内方法学方面的一致程度分别为40%至100%、25%至100%和30%至100%。正式指南比其他组略为同质化。组间比较表明,指南在约75%的方法学方面达成一致。在分析应纳入的视角、资源和成本的选择以及评估所使用资源的方法方面,指南之间存在分歧。
指南组内和组间在方法学要求和建议方面存在协调一致。本综述提供了有关已达成的核心共识的信息。确定了对各方(主要是制药行业)的一些政策影响。